KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Free Cash Flow (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Free Cash Flow for 16 consecutive years, with $212.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 21.36% to $212.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $644.6 million, a 37.62% increase, with the full-year FY2025 number at $644.6 million, up 37.62% from a year prior.
  • Free Cash Flow was $212.9 million for Q4 2025 at Halozyme Therapeutics, up from $180.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $212.9 million in Q4 2025 to a low of $36.4 million in Q2 2021.
  • A 5-year average of $101.0 million and a median of $85.0 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 2130.78% in 2021, then tumbled 43.4% in 2022.
  • Halozyme Therapeutics' Free Cash Flow stood at $82.4 million in 2021, then dropped by 2.73% to $80.1 million in 2022, then increased by 9.34% to $87.6 million in 2023, then soared by 100.26% to $175.4 million in 2024, then increased by 21.36% to $212.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Free Cash Flow are $212.9 million (Q4 2025), $180.3 million (Q3 2025), and $97.7 million (Q2 2025).